ECE. A. Chicherev

E. A. Chicherev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


E. A. Chicherev has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antigen-presenting subsets of neutrophils: A diagnostic marker of clinical efficiency of immunomodulatory therapy with synthetic thymic hexapeptide in children with acute hematogenous osteomyelitis

    by I. V. Nesterova, G. A. Chudilova, N. K. Barova, A. D. Safontseva, E. A. Poezzhaev, S. V. Kovaleva, V. N. Chapurina, E. A. Chicherev, Yu. V. Teterin, L. V. Lomtatidze, et al.

    The multiple functions of neutrophilic granulocytes (NG) are associated with various subsets and phenotypes of these cells. Previously, in children with severe purulent inflammatory diseases, a correlation was found between the severity of disease and contents of CD66b + CD16 + CD33 + HLA-DR + NG (APC-NG) subset. Thus, the determination of the APC-NG subset may serve as a valuable diagnostic tool and an efficiency index during complex therapy in severe purulent-inflammatory diseases. Our goal was to assess the dynamic changes in APC-NG levels in children with AHO in comparison with the dynamics of indicators of clinical effectiveness during immunomodulatory therapy with a synthetic thymic hexapeptide (HP). Materials and methods. The study group (SG) included 15 children aged 10-15 years with acute hematogenic osteomyelitis (AHO), the comparison group (CG) consisted of 13 conditionally healthy children. The contents of NG expressing CD66b, CD16, CD33, HLA-DR (FC500, Beckman Coulter), and expression density of these molecules was evaluated in peripheral blood (PB) of patients and controls. The PB samples were collected before surgery, on the 10 th day of therapy, and before discharge. The immunological parameters of control samples were studied once. The amounts of APC-NG were found to be increased by 18 times in study group before treatment, being decreased by 1.9 times on the 10 th day after the beginning of treatment, and by 3.8 times at the time of discharge (20-25 th day). However, the content of APC-NG after treatment did not reach the CG levels. Moreover, a decreased number of APC-NG correlated with positive clinical dynamics: there was an earlier regression of general and local symptoms. A delay in positive changes of APC-NG was observed in the absence of clinical efficiency, thus requiring a revision of therapeutic strategy, and changes of antibacterial therapy. Conclusion: The study demonstrated high clinical efficacy of thymic HP in the complex treatment of children with AHO and a diagnostic potential of the APC-NG contents as a diagnostic marker for monitoring efficacy of postsurgical treatment of pediatric AHO patients. This marker may also serve as a tool that allows for timely correction of AHO treatment at the in- and outpatient stages.

  • Open Access

    In vitro effects of recombinant IFNα2B on the content of antigen-presenting CD66b+CD16+CD33+HLA-DR+ subset of neutrophils in children with acute osteomyelitis

    by I. V. Nesterova, Galina A. Chudilova, Yu. V. Teterin, E. A. Chicherev, V. N. Chapurina, V. A. Tarakanov, N. K. Barova

    Negative impact of S. aureus, seems to be a sufficient condition for the spread of the infectious process in the bone in acute osteomyelitis (AOM) due to its altered elimination caused by dysfunction of the immune system (IS), in particular, of neutrophilic granulocytes (NG). Correction of NG dysfunction in AOM under the influence of immunotropic substances and cytokines via modulation of the NG phenotypic subsets is of sufficient interest. Our aim was to evaluate the in vitro effects of recombinant IFNá2b on the number and phenotype of CD66b+CD16+CD33+HLA-DR-, CD66b+CD16+CD33+HLA-DR+ subsets and on phagocytic function of neutrophilic granulocytes in acute osteomyelitis in children. The study of peripheral blood (PB) samples from children aged 8-15 years was carried out as follows: patients with АOM (n = 24) comprised study group 1 (SG1), healthy children (n = 13) were included into comparison group (CG). PB samples of children with AOM were incubated with recIFNá2b (50 IU/µL, 60 min, 37 °C.) in the study group 1a (SG1a). Before and after incubation with recIFNá2b, the number of NG subsets CD66b+CD16+CD33+HLA-DR-, CD66b+CD16+CD33+HLA-DR+ and the density values of receptor expression by fluorescence intensity (MFI) were also determined (FC 500, Beckman Coulter, США). Phagocytic activity of NCs was evaluated as the contents of actively phagocytic NCs (%PhAN), volume of the engulfed S. aureus (strain 209) by assessing their phagocytic number (PhN), phagocytic index (PhI). Bacterial killing was determined as the percentages of microbe digestion (%D), digestion index (DI). The cells from AOM patients revealed a subset expressing the HLA-DR receptor – СD66b+CD16+CD33+HLA-DR+NG, which is absent in the PB of CG children. The cells with primed phenotype exhibited an increased expression density of activation receptors CD16 and CD66b. Incubation of PB in AOM with recIFNá2b led to an increased proportion of CD66b+CD16+CD33+HLA-DR+ NG subset which showed active phagocytosis and improved digestion processes. The present study shows the emergence of activated subset of “long-lived” CD66b+CD16+CD33+HLA-DR+ NCs in children with AOM. This subpopulation has APC features, by presenting AG to T lymphocytes, with preserved effector properties. In an in vitro experimental system, a positive effect of recIFNá2b was demonstrated, leading to an increased number of NGs of the CD66b+CD16+CD33+HLA-DR+ subset and recovery of S. aureus phagocytosis by NGs, thus being promising in the future for development of new approaches to optimization of complex therapy in the postoperative period of AOM treatment, prevention of complications and the opportunity to alleviate the disorders in the immune system.

  • Open Access

    Clinical and immunological efficacy of the immunomodulating hexapeptide arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine in the complex postoperative treatment of children with acute osteomyelitis

    by Galina A. Chudilova, E. A. Chicherev, Yu. V. Teterin, V. N. Chapurina, V. A. Tarakanov, N. K. Barova, I. V. Nesterova

    The recurrent and persistent nature of osteomyelitis, like as associated high morbidity of patients, prolonged hospitalization and expensive treatment require development of new approaches in therapy and pathogenetic justification of the immunotropic drugs usage in complex etiopathogenetic treatment of this disorder. Our objective was to evaluate the clinical and immunological efficacy of hexapeptide (HP), arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine implemented in the complex treatment of acute osteomyelitis in children during the postoperative period. 19 children aged 8-15 years with acute osteomyelitis (AOM) were studied: the study group 1 (SG1, n = 11) received a standard treatment at all the disease stages; in study group 2 (SG2, n = 8), the standard therapy was supplemented with a medical drug Imunofan, containing hexapeptide (НP) as the active substance. Prior and after the course of drug treatment, we determined the following parameters: the contents of T cells (CD3+CD19-, CD3+CD4+, CD3+CD8+, CD3+CD4+/CD3+CD8+) and B cells (CD3-CD19+), NK (CD3-CD16+CD56+) by means of Cytomics FC-500 (“Веckman Coulter”, USA), the levels of serum IgA, IgM, IgG (ELISA tests), assessment of phagocytic activity of neutrophil granulocytes (NG) with determining the ratio of actively phagocytic NG (%PhAN), capture processes (PhN, PhI) and the completeness of phagocytosis (%D, DI) tested with S. aureus (strain No. 209). In the studied groups with AOM, a decreased content of T lymphocytes, T helper cells, T lymphocytes, NK cells was revealed, along with unchanged content of B lymphocytes. In SG2, the increased IgA and IgG levesl have been shown. We have also revealed a deficiency of phagocytic function associated with the processes of phagocytosis completion. The use of immunomodulatory therapy with an HP-containing pharmaceutical drug in combination with standard treatment was associated with restoration of immunological parameters to the reference values of healthy children, thus leading to shorter febrile period, milder manifestations of intoxication, earlier periods of reconvalescence from purulent-inflammatory process, and reduced hospital stay. The obtained positive clinical and immunological effects demonstrate the expediency of targeted immunomodulatory therapy including a pharmaceutical HP-containing drug as the active substance in the complex postoperative treatment of children with AOM. Restoration of the disturbed mechanisms of anti-infectious immunity in AOM under usage of immunomodulating HP contributes to more effective elimination of pathogens and, as a result, improvement of the clinical course of the disease, as well as prevention of chronic inflammatory processes and aggravation of immune system dysfunction.